Vertex Pharmaceuticals (VRTX) Net Margin (2009 - 2026)
Vertex Pharmaceuticals' quarterly Net Margin came in at 34.53% in Q1 2026, up 1120.0% year-on-year from 2.83% in Q1 2025, and down 7.52% quarter-over-quarter from 37.34% in Q4 2025.
Vertex Pharmaceuticals has reported Net Margin for 18 years, with the latest figure at 34.53% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 1120.0% year-over-year to 34.53%; the trailing twelve-month figure through Mar 2026 stood at 35.51% (up 4442.0% YoY), and the FY2025 full-year result was 32.94%, up 3780.0% from the prior year.
- Net Margin for Q1 2026 stood at 34.53%, down from 37.34% in the prior quarter.
- The five-year high for Net Margin was 41.69% in Q3 2023, with the low at 135.83% in Q2 2024.
- Average Net Margin over 5 years is 25.55%, with a median of 36.33% recorded in 2022.
- Year-over-year, Net Margin tumbled 17256 bps in 2024 and soared 17067 bps in 2025.
- Tracing VRTX's Net Margin over 5 years: stood at 35.56% in 2022, then increased by 8 bps to 38.48% in 2023, then retreated by 19 bps to 31.35% in 2024, then increased by 19 bps to 37.34% in 2025, then fell by 8 bps to 34.53% in 2026.
- The last three Net Margin figures came in at 34.53% (Q1 2026), 37.34% (Q4 2025), and 35.2% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.53% |
| Dec 31, 2025 | 37.34% |
| Sep 30, 2025 | 35.20% |
| Jun 30, 2025 | 34.84% |
| Mar 31, 2025 | 23.33% |
| Dec 31, 2024 | 31.35% |
| Sep 30, 2024 | 37.71% |
| Jun 30, 2024 | -135.83% |
| Mar 31, 2024 | 40.87% |
| Dec 31, 2023 | 38.48% |
| Sep 30, 2023 | 41.69% |
| Jun 30, 2023 | 36.73% |
| Mar 31, 2023 | 29.47% |
| Dec 31, 2022 | 35.56% |
| Sep 30, 2022 | 39.86% |
| Jun 30, 2022 | 36.90% |
| Mar 31, 2022 | 36.33% |
| Dec 31, 2021 | 37.16% |
| Sep 30, 2021 | 42.94% |
| Jun 30, 2021 | 3.74% |
| Mar 31, 2021 | 37.88% |
| Dec 31, 2020 | 37.12% |
| Sep 30, 2020 | 43.39% |
| Jun 30, 2020 | 54.92% |
| Mar 31, 2020 | 39.78% |
| Dec 31, 2019 | 374.35% |
| Sep 30, 2019 | 6.06% |
| Jun 30, 2019 | 28.41% |
| Mar 31, 2019 | 31.29% |
| Dec 31, 2018 | 175.28% |
| Sep 30, 2018 | 12.76% |
| Jun 30, 2018 | 23.61% |
| Mar 31, 2018 | 30.83% |
| Dec 31, 2017 | 13.57% |
| Sep 30, 2017 | -52.43% |
| Jun 30, 2017 | -30.28% |
| Mar 31, 2017 | 9.34% |
| Dec 31, 2016 | -33.54% |
| Sep 30, 2016 | -55.24% |
| Jun 30, 2016 | -52.54% |
| Mar 31, 2016 | -49.04% |
| Dec 31, 2015 | -37.80% |
| Sep 30, 2015 | -51.10% |
| Jun 30, 2015 | -92.28% |
| Mar 31, 2015 | -16.11% |
| Dec 31, 2014 | -14.79% |
| Sep 30, 2014 | -0.05% |
| Jun 30, 2014 | -0.24% |
| Mar 31, 2014 | -0.29% |
| Dec 31, 2013 | -127.02% |
| Sep 30, 2013 | -85.42% |
| Jun 30, 2013 | -74.50% |
| Mar 31, 2013 | -60.17% |
| Dec 31, 2012 | -82.26% |
| Sep 30, 2012 | -7.88% |
| Jun 30, 2012 | -8.24% |
| Mar 31, 2012 | 23.41% |
| Dec 31, 2011 | 28.11% |
| Sep 30, 2011 | 52.19% |
| Mar 31, 2011 | -239.06% |
| Dec 31, 2010 | -275.31% |
| Sep 30, 2010 | -878.16% |
| Jun 30, 2010 | -632.49% |
| Mar 31, 2010 | -730.22% |
| Dec 31, 2009 | -445.44% |
| Sep 30, 2009 | -599.29% |
| Jun 30, 2009 | -834.05% |
| Mar 31, 2009 | -678.39% |